No Evidence that <i>CD33</i> rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

<div>Mechanism of action of GO. Abbreviations: GO: gemtuzumab ozogamicin.</div>

Disease Markers

fig1

Figure 1

Figure 1: No Evidence that <i>CD33</i> rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group 

Figure 1 | No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group 